Katayama I, Otoyama K, Kondo S, Nishioka K, Nishiyama S
Department of Dermatology, Kitasato University School of Medicine, Kanagawa, Japan.
J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):198-201. doi: 10.1016/0190-9622(90)70198-q.
Anticardiolipin antibody-positive patients with progressive systemic sclerosis were analyzed. Elevated anticardiolipin antibody titers were observed in 13 of 40 cases (33%). Anticardiolipin antibody titer was significantly higher in patients with progressive systemic sclerosis type 1 than in those with type 2 or type 3. Occurrence of anticardiolipin antibody was significantly more frequent in patients positive for anti-nRNP antibodies, rheumatoid factor, or thrombocytopenia. In contrast, patients with proximal scleroderma, scarring, or esophageal hypomotility were positive for anticardiolipin antibody less frequently. These results suggest that anticardiolipin antibody might be closely associated with lupuslike clinical manifestations in a subset of progressive systemic sclerosis or definite progressive systemic sclerosis with thrombocytopenia, rheumatoid factor, or anti-nRNP antibodies.
对患有进行性系统性硬化症且抗心磷脂抗体呈阳性的患者进行了分析。40例患者中有13例（33%）观察到抗心磷脂抗体滴度升高。1型进行性系统性硬化症患者的抗心磷脂抗体滴度显著高于2型或3型患者。抗nRNP抗体、类风湿因子或血小板减少症呈阳性的患者中，抗心磷脂抗体的出现频率显著更高。相比之下，近端硬皮病、瘢痕形成或食管动力不足的患者抗心磷脂抗体阳性的频率较低。这些结果表明，抗心磷脂抗体可能与进行性系统性硬化症或伴有血小板减少症、类风湿因子或抗nRNP抗体的明确进行性系统性硬化症亚组中的狼疮样临床表现密切相关。
